Today’s breakthroughs can’t use yesterday’s solutions.
Cell and gene therapies that are creating new possibilities for patients deserve commercialization strategies that are just as pioneering.
AmerisourceBergen understands that new therapies demand a supply chain that’s willing to evolve. With businesses at the forefront of each commercialization touch point – and a history of supporting the launch of nearly every single biologic and specialty pharmaceutical product that has entered the market over the past 20 years – AmerisourceBergen is the trusted partner for cell and gene therapy innovators. From specialty logistics and market access consulting to patient support and the analysis of health outcomes, AmerisourceBergen provides the solutions that help your therapy fulfill its promise.
AmerisourceBergen's portfolio of businesses works in tandem with you – and with each other – to drive your success.
Coordination is a must
World Courier facilitates coordinated peripheral scheduling to ensure a pinpoint pickup as well as real-time product tracking. We also boast advanced cyroshipping technologies and practices that involve kitting at the apheresis to ensure the product’s stability and visibility.
Overcome regulatory hurdles
Xcenda leverages market access and health economics expertise to prove a therapy’s clinical benefit and demonstrate its safety, efficacy and cost-effectiveness. That data is transformed into a strong, credible and persuasive value story that helps smooth regulatory pathways.
Support that's the first of its kind
Xcenda has also pioneered field reimbursement support to educate providers and enable their staff to manage complex product access requirements, like those associated with emerging medication classes.
An undivided focus
ICS provides integrated logistics – including supportive product storage, customer service, order-to-cash financial management and different models for product distribution, all of which can work together to reduce financial risk and operational burden.